Liarozole (BioDeep_00001871526)
代谢物信息卡片
化学式: C17H13ClN4 (308.0828688)
中文名称: 利阿唑
谱图信息:
最多检出来源 () 0%
分子结构信息
SMILES: C1=CC(=CC(=C1)Cl)C(C2=CC3=C(C=C2)N=CN3)N4C=CN=C4
InChI: InChI=1S/C17H13ClN4/c18-14-3-1-2-12(8-14)17(22-7-6-19-11-22)13-4-5-15-16(9-13)21-10-20-15/h1-11,17H,(H,20,21)
描述信息
D006730 - Hormones, Hormone Substitutes, and Hormone Antagonists > D006727 - Hormone Antagonists > D000726 - Androgen Antagonists
C274 - Antineoplastic Agent > C2189 - Signal Transduction Inhibitor > C129824 - Antineoplastic Protein Inhibitor
C274 - Antineoplastic Agent > C129818 - Antineoplastic Hormonal/Endocrine Agent > C481 - Antiestrogen
C274 - Antineoplastic Agent > C163758 - Targeted Therapy Agent > C1740 - Aromatase Inhibitor
C471 - Enzyme Inhibitor > C129825 - Antineoplastic Enzyme Inhibitor
C147908 - Hormone Therapy Agent > C547 - Hormone Antagonist
D000970 - Antineoplastic Agents
D003879 - Dermatologic Agents
D004791 - Enzyme Inhibitors
同义名列表
1 个代谢物同义名
数据库引用编号
7 个数据库交叉引用编号
- ChEBI: CHEBI:135316
- PubChem: 60652
- DrugBank: DB13066
- ChEMBL: CHEMBL389433
- CAS: 172282-43-8
- CAS: 115575-11-6
- CAS: 171849-18-6
分类词条
相关代谢途径
Reactome(0)
BioCyc(0)
PlantCyc(0)
代谢反应
0 个相关的代谢反应过程信息。
Reactome(0)
BioCyc(0)
WikiPathways(0)
Plant Reactome(0)
INOH(0)
PlantCyc(0)
COVID-19 Disease Map(0)
PathBank(0)
PharmGKB(0)
0 个相关的物种来源信息
在这里通过桑基图来展示出与当前的这个代谢物在我们的BioDeep知识库中具有相关联信息的其他代谢物。在这里进行关联的信息来源主要有：
- PubMed: 来源于PubMed文献库中的文献信息，我们通过自然语言数据挖掘得到的在同一篇文献中被同时提及的相关代谢物列表，这个列表按照代谢物同时出现的文献数量降序排序，取前10个代谢物作为相关研究中关联性很高的代谢物集合展示在桑基图中。
- NCBI Taxonomy: 通过文献数据挖掘，得到的代谢物物种来源信息关联。这个关联信息同样按照出现的次数降序排序，取前10个代谢物作为高关联度的代谢物集合展示在桑吉图上。
- Chemical Taxonomy: 在物质分类上处于同一个分类集合中的其他代谢物
- Chemical Reaction: 在化学反应过程中，存在为当前代谢物相关联的生化反应过程中的反应底物或者反应产物的关联代谢物信息。
点击图上的相关代谢物的名称，可以跳转到相关代谢物的信息页面。
文献列表
- M Bhushan, A D Burden, K McElhone, R James, F P Vanhoutte, C E Griffiths. Oral liarozole in the treatment of palmoplantar pustular psoriasis: a randomized, double-blind, placebo-controlled study.
The British journal of dermatology.
2001 Oct; 145(4):546-53. doi:
10.1046/j.1365-2133.2001.04411.x. [PMID: 11703279] - J Berth-Jones, G Todd, P E Hutchinson, K Thestrup-Pedersen, F P Vanhoutte. Treatment of psoriasis with oral liarozole: a dose-ranging study.
The British journal of dermatology.
2000 Dec; 143(6):1170-6. doi:
10.1046/j.1365-2133.2000.03884.x. [PMID: 11122017] - P E Goss, K Strasser, R Marques, M Clemons, A Oza, R Goel, M Blackstein, L Kaizer, E E Sterns, J M Nabholtz, R De Coster, M Crump, M Abdolell, S Qi. Liarozole fumarate (R85246): in the treatment of ER negative, tamoxifen refractory or chemotherapy resistant postmenopausal metastatic breast cancer.
Breast cancer research and treatment.
2000 Nov; 64(2):177-88. doi:
10.1023/a:1006480504790. [PMID: 11194453] - Q Zeng, D C Smith, T J Suscovich, W E Gooding, D L Trump, J R Grandis. Determination of intermediate biomarker expression levels by quantitative reverse transcription-polymerase chain reaction in oral mucosa of cancer patients treated with liarozole.
Clinical cancer research : an official journal of the American Association for Cancer Research.
2000 Jun; 6(6):2245-51. doi:
. [PMID: 10873074] - R Parthasarathy, K Mehta. Altered metabolism of all-trans-retinoic acid in liposome-encapsulated form.
Cancer letters.
1998 Dec; 134(2):121-8. doi:
10.1016/s0304-3835(98)00226-2. [PMID: 10025871] - Y Ideyama, M Kudoh, K Tanimoto, Y Susaki, T Nanya, T Nakahara, H Ishikawa, T Yoden, M Okada, T Fujikura, H Akaza, H Shikama. Novel nonsteroidal inhibitor of cytochrome P450(17alpha) (17alpha-hydroxylase/C17-20 lyase), YM116, decreased prostatic weights by reducing serum concentrations of testosterone and adrenal androgens in rats.
The Prostate.
1998 Sep; 37(1):10-8. doi:
10.1002/(sici)1097-0045(19980915)37:1<10::aid-pros3>3.0.co;2-c. [PMID: 9721064] - A L Kuijpers, J P Van Pelt, M Bergers, P J Boegheim, J E Den Bakker, G Siegenthaler, P C Van de Kerkhof, J Schalkwijk. The effects of oral liarozole on epidermal proliferation and differentiation in severe plaque psoriasis are comparable with those of acitretin.
The British journal of dermatology.
1998 Sep; 139(3):380-9. doi:
10.1046/j.1365-2133.1998.02399.x. [PMID: 9988537] - L Denis, F Debruyne, P De Porre, J Bruynseels. Early clinical experience with liarozole (Liazal) in patients with progressive prostate cancer.
European journal of cancer (Oxford, England : 1990).
1998 Mar; 34(4):469-75. doi:
10.1016/s0959-8049(97)10120-4. [PMID: 9713295] - H Akaza. [Development of new drugs for urological cancers].
Gan to kagaku ryoho. Cancer & chemotherapy.
1997 Oct; 24(13):1938-40. doi:
. [PMID: 9350239] - R De Coster, W Wouters, J Bruynseels. P450-dependent enzymes as targets for prostate cancer therapy.
The Journal of steroid biochemistry and molecular biology.
1996 Jan; 56(1-6 Spec No):133-43. doi:
10.1016/0960-0760(95)00230-8. [PMID: 8603034] - P Acevedo, J S Bertram. Liarozole potentiates the cancer chemopreventive activity of and the up-regulation of gap junctional communication and connexin43 expression by retinoic acid and beta-carotene in 10T1/2 cells.
Carcinogenesis.
1995 Sep; 16(9):2215-22. doi:
10.1093/carcin/16.9.2215. [PMID: 7554078] - G Smets, R Van Ginckel, G Daneels, M Moeremans, J Van Wauwe, M C Coene, F C Ramaekers, J A Schalken, M Borgers, R De Coster. Liarozole, an antitumor drug, modulates cytokeratin expression in the Dunning AT-6sq prostatic carcinoma through in situ accumulation of all-trans-retinoic acid.
The Prostate.
1995 Sep; 27(3):129-40. doi:
10.1002/pros.2990270303. [PMID: 7567691] - P Dockx, J Decree, H Degreef. Inhibition of the metabolism of endogenous retinoic acid as treatment for severe psoriasis: an open study with oral liarozole.
The British journal of dermatology.
1995 Sep; 133(3):426-32. doi:
10.1111/j.1365-2133.1995.tb02672.x. [PMID: 8546999] - C C Achkar, J M Bentel, J F Boylan, H I Scher, L J Gudas, W H Miller. Differences in the pharmacokinetic properties of orally administered all-trans-retinoic acid and 9-cis-retinoic acid in the plasma of nude mice.
Drug metabolism and disposition: the biological fate of chemicals.
1994 May; 22(3):451-8. doi:
NULL. [PMID: 8070324] - J Van Wauwe, M C Coene, W Cools, J Goossens, W Lauwers, L Le Jeune, C Van Hove, G Van Nyen. Liarozole fumarate inhibits the metabolism of 4-keto-all-trans-retinoic acid.
Biochemical pharmacology.
1994 Feb; 47(4):737-41. doi:
10.1016/0006-2952(94)90137-6. [PMID: 8129749] - V A Miller, J R Rigas, J R Muindi, W P Tong, E Venkatraman, M G Kris, R P Warrell. Modulation of all-trans retinoic acid pharmacokinetics by liarozole.
Cancer chemotherapy and pharmacology.
1994; 34(6):522-6. doi:
10.1007/bf00685665. [PMID: 7923564] - U Vollmer, B W Müller, J Peeters, J Mesens, B Wilffert, T Peters. A study of the percutaneous absorption-enhancing effects of cyclodextrin derivatives in rats.
The Journal of pharmacy and pharmacology.
1994 Jan; 46(1):19-22. doi:
10.1111/j.2042-7158.1994.tb03713.x. [PMID: 8201522] - M E Westarp, M P Westarp, W Grundl, H Biesalski, H H Kornhuber. Improving medical approaches to primary CNS malignancies--retinoid therapy and more.
Medical hypotheses.
1993 Sep; 41(3):267-76. doi:
10.1016/0306-9877(93)90246-m. [PMID: 8259089] - J Van Wauwe, G Van Nyen, M C Coene, P Stoppie, W Cools, J Goossens, P Borghgraef, P A Janssen. Liarozole, an inhibitor of retinoic acid metabolism, exerts retinoid-mimetic effects in vivo.
The Journal of pharmacology and experimental therapeutics.
1992 May; 261(2):773-9. doi:
NULL. [PMID: 1374473] - J P Van Wauwe, M C Coene, J Goossens, W Cools, J Monbaliu. Effects of cytochrome P-450 inhibitors on the in vivo metabolism of all-trans-retinoic acid in rats.
The Journal of pharmacology and experimental therapeutics.
1990 Jan; 252(1):365-9. doi:
NULL. [PMID: 2299598] - J Bruynseels, R De Coster, P Van Rooy, W Wouters, M C Coene, E Snoeck, A Raeymaekers, E Freyne, G Sanz, G Vanden Bussche. R 75251, a new inhibitor of steroid biosynthesis.
The Prostate.
1990; 16(4):345-57. doi:
10.1002/pros.2990160409. [PMID: 2164659] - R Van Ginckel, R De Coster, W Wouters, W Vanherck, R van der Veer, N Goeminne, E Jagers, H Van Cauteren, L Wouters, W Distelmans. Antitumoral effects of R 75251 on the growth of transplantable R3327 prostatic adenocarcinoma in rats.
The Prostate.
1990; 16(4):313-23. doi:
10.1002/pros.2990160406. [PMID: 2371176]